FibroBiologics Announces 1-for-20 Reverse Stock Split Effective March 30, 2026

On March 30, 2026, FibroBiologics, Inc. implemented a one-for-twenty (1:20) reverse stock split of its issued and outstanding common stock. The corporate action was authorized following a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation filed on March 25, 2026. As a result of the split, every 20 shares of common stock were automatically converted into one share. No fractional shares were issued; instead, any fractional interests were rounded up to the nearest whole share. The reverse stock split was designed to affect all stockholders uniformly without altering percentage ownership interests, except for minor adjustments due to rounding. The Company’s trading symbol remains 'FBLG' on The Nasdaq Stock Market, though a new CUSIP number (31573L204) has been assigned. The split also resulted in proportionate adjustments to the Company’s equity incentive plans, including the exercise prices and number of shares underlying outstanding stock options and warrants. The par value and the total number of authorized shares of common stock remained unchanged.